Report Highlights
The global protein drugs market should reach $394.2 billion by 2026 from $265.0 billion in 2021 at a compound annual growth rate (CAGR) of 8.3% for the forecast period of 2021 to 2026.
Report Includes
- 37 data tables and 28 additional tables
- An overview of the global markets and manufacturing technologies for protein drugs
- Estimation of the market size and analyses of global market trends, with data from 2019 to 2020, estimates for 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the current and future market potential and quantification of protein drugs market based on type, manufacturing process and region
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Detailed description of protein drugs, their classification and six main manufacturing technologies and information on recombinant deoxyribonucleic acid (rDNA) technology
- Information on advancements in manufacturing technologies, new product launches of the industry and discussion on effect of biosimilars entry to the protein drugs market
- Detailed analysis of the regulatory framework and policies and technological changes within the industry
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players of the industry, including AbbVie Inc., Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer Inc. and Sanofi S.A.
Report Scope
This report will focus on protein drugs, classification and manufacturing technologies. The protein drugs market can be classified into peptide hormones, monoclonal antibodies, cytokines, therapeutic enzymes, blood factors, vaccines and peptide antibiotics. This report focuses on six techniques for manufacturing protein therapeutics, including fractionation from natural human/animal sources, microbial fermentation, cell culture, chemical synthesis, transgenics and embryonated eggs. The report focuses on each market and its applications, regulatory environment, latest trends and developments, drivers, restraints and challenges affecting the market.
The report covers company profiles for all the major companies and also company share analysis. This report also covers market projections to 2026 and relevant patent analysis. By geography, the market has been segmented into the United States, Europe and emerging markets. Emerging markets include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand. For market estimates, data has been provided for the year 2019, 2020 (as base year) and forecast through 2026.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
- Cell and Gene Therapy Tools, and Reagents: Global Markets (BIO208C)
- Single-use Technologies for Biopharmaceuticals: Global Markets (BIO099F)
- Induced Pluripotent Stem Cells: Global Markets (BIO135F)
- Commercial Amino Acids (BIO007N)
- Technical Textiles: Global Markets (CHM136C)
Report Highlights
The global protein drugs market reached nearly $174.7 billion in 2015 and should reach nearly $248.7 billion by 2020 at a compound annual growth rate (CAGR) of 7.3% through 2020.
Report Includes
- An overview of the markets for each major class of protein in the segments therapeutic monoclonal antibodies, cytokines, peptide hormones, vaccines, and blood products
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
- Discussion covering the strength and weaknesses of each type of technology in light of the new technologies, growing competition, and changing customer needs
- Examinations of current successes, including the size and sales forecast for each class in the next five years
- Evaluation of challenges such as delivery methods and side effects
- Consideration of issues regarding add-on products and patent protection
- Company profiles of major players
Report Highlights
The global protein therapeutics market reached $138.3 billion in 2012. This market is expected to decline to $136.7 billion in 2013 and then increase to nearly $179.1 billion in 2018, a compound annual growth rate (CAGR) of 5.6% over the five-year period from 2013 to 2018.
Report Includes
- An overview of the markets for each major class of protein in the segments therapeutic monoclonal antibodies, cytokines, peptide hormones, vaccines, and blood products
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
- Examinations of current successes, including the size and sales forecast for each class in the next five years
- Discussion of challenges such as delivery methods and side effects
- Consideration of issues regarding add-on products and patent protection
- Comprehensive company profiles of major players.
Report Highlights
- The global market for protein drugs is expected to increase from $86.8 billion in 2007 to an estimated $95.2 billion in 2008 and $160.1 billion in 2013, a compound annual growth rate (CAGR) of 10.9%.
- Peptide hormones generated $26.1 billion in 2007 and an estimated $27.9 billion in 2008. This segment should reach $50.4 billion in 2013, for a CAGR of 12.6%.
- The antibodies segment was worth $15.0 billion in 2007. This is expected to increase to $18.1 billion in 2008 and $36.9 billion in 2013, for a CAGR of 15.4%.
Report Highlights
-
Protein drugs for human therapeutic use are a 1,000 metric ton industry-more than one billion grams of bulk proteins that garnered formulation sales, on average, of $27.80 per gram in 1999. This study estimates 1,048,859,344 grams of bulk drug proteins were produced worldwide in 1999. Approximately 1,150,573,386 grams will be produced worldwide in 2004, representing an overall 1.9% average annual (compound) growth rate from 1999 to 2004.
-
Recombinant biological methods provided only 0.1% of the worldwide total bulk drug protein production in 1999, but are projected to provide 0.6% of the total production in 2004.
Related Reports
Excipients in Pharmaceuticals: Global Markets to 2029
The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.
Antibody Drugs: Technologies and Global Markets
The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.
Global Markets for Vaccine Technologies
The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.
Biologic Therapeutic Drugs: Technologies and Global Markets
The global market for biological therapeutic drugs is expected to increase from $452.9 billion in 2023 to $823.4 billion by the end of 2028, with a compound annual growth rate (CAGR) of 12.7% during the forecast period of 2023-2028.
Recent Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
Commercial Amino Acids
The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Top Trending Reports
AI in Clinical and Molecular Diagnostics Market
The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Medical Devices: Technologies and Global Markets
The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Artificial Intelligence (AI) Market: Investments vs Potential
The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More